These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10971132)

  • 21. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
    Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
    Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins.
    Fernández M; Quiroga JA; Carreño V
    J Gen Virol; 2003 Aug; 84(Pt 8):2073-2082. PubMed ID: 12867637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-nucleotide polymorphism in the promoter region of the osteopontin gene at nucleotide -443 as a marker predicting the efficacy of pegylated interferon/ribavirin-therapy in Egyptians patients with chronic hepatitis C.
    Shaker OG; Sadik NA; El-Dessouki A
    Hum Immunol; 2012 Oct; 73(10):1039-45. PubMed ID: 22836041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single nucleotide polymorphisms and functional analysis of MxA promoter region in multiple sclerosis.
    Furuyama H; Chiba S; Okabayashi T; Yokota S; Nonaka M; Imai T; Fujii N; Matsumoto H
    J Neurol Sci; 2006 Nov; 249(2):153-7. PubMed ID: 16843495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.
    Ali FT; Ali MA; Elgizawy MM; Elsawy AM
    Gut Liver; 2015 Jul; 9(4):516-24. PubMed ID: 25717047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection.
    MacQuillan GC; de Boer WB; Platten MA; McCaul KA; Reed WD; Jeffrey GP; Allan JE
    J Med Virol; 2002 Oct; 68(2):197-205. PubMed ID: 12210408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association with 5'-untranslated region and response to interferon in chronic hepatitis C.
    Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    Hepatogastroenterology; 2007; 54(75):854-7. PubMed ID: 17591078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study.
    King JK; Yeh SH; Lin MW; Liu CJ; Lai MY; Kao JH; Chen DS; Chen PJ
    Hepatology; 2002 Dec; 36(6):1416-24. PubMed ID: 12447867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Structural analysis of the PKR-binding region of HCV 1b samples from patients with chronic hepatitis C and the correlation with IFN-sensitivity].
    Gervain J; Czibula A; Simon J; Kalmár T
    Orv Hetil; 2003 Jun; 144(24):1179-84. PubMed ID: 12866147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.
    Tsukada H; Ochi H; Maekawa T; Abe H; Fujimoto Y; Tsuge M; Takahashi H; Kumada H; Kamatani N; Nakamura Y; Chayama K
    Gastroenterology; 2009 May; 136(5):1796-805.e6. PubMed ID: 19208361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation.
    François C; Bernard I; Castelain S; Charleston B; Fray MD; Capiod JC; Duverlie G
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3770-5. PubMed ID: 16127052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan.
    Konishi I; Horiike N; Hiasa Y; Michitaka K; Onji M
    Intervirology; 2004; 47(2):114-20. PubMed ID: 15192276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcriptional response of MxA, PKR and SOCS3 to interferon-based therapy in HCV genotype 4-infected patients and contribution of p53 to host antiviral response.
    Hamdi N; El-Akel W; El-Serafy M; Esmat G; Sarrazin C; Abdelaziz AI
    Intervirology; 2012; 55(3):210-8. PubMed ID: 21597279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of OAS1 gene polymorphism at exon 7 splice accepter site with interferon-based therapy of HCV infection in Pakistan.
    Imran M; Manzoor S; Khattak NM; Tariq M; Khalid M; Javed F; Bhatti S
    Viral Immunol; 2014 Apr; 27(3):105-11. PubMed ID: 24673406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection.
    El-Karaksy HM; Sharaf SA; Mandour IA; Mogahed EA; Rady NH; El-Mougy FA
    Hum Immunol; 2016 Dec; 77(12):1248-1253. PubMed ID: 27660094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of FokI (rs10735810) and BsmI (rs1544410) on Treatment of Chronic HCV Patients With Genotype 4.
    Shaker O; Nassar Y; Ayoub S; Elrazki M; Zahra A
    J Clin Lab Anal; 2016 Nov; 30(6):1021-1027. PubMed ID: 27087054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen-related MxA transcriptional variation in hepatitis C virus-infected patients.
    Mekky RY; Hamdi N; El-Akel W; Esmat G; Abdelaziz AI
    Transl Res; 2012 Mar; 159(3):190-6. PubMed ID: 22340769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection.
    Yee LJ; Tang J; Gibson AW; Kimberly R; Van Leeuwen DJ; Kaslow RA
    Hepatology; 2001 Mar; 33(3):708-12. PubMed ID: 11230752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional characterization of new allelic polymorphisms identified in the promoter region of the human MxA gene.
    Tran Thi Duc T; Desmecht D; Cornet A
    Int J Immunogenet; 2013 Aug; 40(4):316-9. PubMed ID: 22985419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.